Latest:
Dr. Greten on the Tumor Microbiome and Antitumor Immunity in Liver Cancer
Tim F. Greten, MD, discusses the role of the gut microbiome in antitumor immunity in liver cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Tim Iveson, MD, FACP
Latest:
Dr. Iveson on the IDEA Collaboration in CRC
Tim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.
Timothy D. Shafman, MD
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology Care
USPSTF guidelines may have decreased the number of patients presenting with prostate
cancer for radiation oncology care, particularly those with low-risk disease, without a
short-term increase in higher-risk disease.
Timothy Fenske, MD, MS
Timothy S. Fenske, MD, MS, is a medical oncologist and professor of medicine at the Froedtert & Medical College of Wisconsin.
Latest:
Dr Fenske on Assessing the Role of Auto-HCT in the Current MCL Treatment Paradigm
Timothy S. Fenske, MD, MS, discusses the rationale for evaluating the role of standard auto-HCT in MCL given recent updates to the MCL treatment paradigm.
Timothy P. Hughes, MD
Latest:
Dr. Hughes on Switching From Imatinib to Nilotinib in CML
Timothy P. Hughes, MD, MBBS, explains the two-year follow-up results of the ENESTcmr trial analyzing the switch to nilotinib after at least 2 years on imatinib in patients with chronic phase chronic myeloid leukemia.
Tina Cascone, MD, PhD
Tina Cascone, MD, PhD, is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.
Latest:
Closing Perspectives: Unmet Needs, Emerging Advances, and the Future of Early-Stage NSCLC Treatment
Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.